Q3 2023

Filed Oct 31, 2023 · 10-Q · 31 days after period end · 0001826466-23-000038

Q3 2023 · 10-Q

Revenue

$0.00

derived— vs Q3 2022

Net Income

-$10.14K

N/M vs Q3 2022

EPS, diluted—

Operating Income-$10,143N/M

Same quarter

Metric	Q3 2023	Q3 2022	Q3 2021	Q3 2020
Revenue	$0.00	$0.00	—	—
Net Income	-$10.14K	$6.34K	-$2.70K	-$160.00
EPS Diluted	—	$0.00	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Nika Pharmaceuticals, Inc · CIK 1145604 · Engraved from SEC EDGAR